Thus, both the EBP50 gain-of-function and loss-of-function studies by CCK-8 and BrdU incorporation assay demonstrated that EBP50 inhibited EGF-induced cell proliferation in MCF-7 and MDA-MB-231 breast cancer cells. Here, NHERF1 is linked to breast cancer.